# Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease

> **NCT03535935** · PHASE2,PHASE3 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 118 (estimated)

## Conditions studied

- Diabetic Nephropathies
- Diabetic Kidney Disease

## Interventions

- **DRUG:** Astragalus Powder
- **OTHER:** Routine medical care (active comparator)

## Key facts

- **NCT ID:** NCT03535935
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2020-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535935, "Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03535935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*